Kano Rui, Sugita Takashi, Kamata Hiroshi
Department of Veterinary Pathobiology, Nihon University College of Bioresouce Sciences.
Department of Microbiology, Meiji Pharmaceutical University.
Med Mycol J. 2020;61(1):11-13. doi: 10.3314/mmj.19-00016.
Ravuconazole (RVCZ) is a newly available human azole drug in Japan since 2018 and is a broad-spectrum antifungal agent that exhibits excellent activity against Candida albicans and Cryptococcus neoformans (formerly: Cryptococcus grubii). The drug is also highly active against isolates that are resistant to fluconazole (FLCZ). In the present study, the in vitro susceptibility to ravuconazole (RVCZ) of Japanese clinical isolates and multi-azole-resistant strains of C. neoformans was investigated using the Clinical & Laboratory Standards Institute (CLSI) M27-A3 test. The minimum inhibitory concentrations for the 14 clinical isolates and the multi-azole-resistant strains were 0.003125-0.125 mg/L and 0.25-0.5 mg/L for RVCZ, respectively. RVCZ is as effective as ITCZ and VRCZ for treating clinical isolates from cats and humans. Moreover, RVCZ is highly effective against multi-azole-resistant strains that encode a protein with a G344S substitution in ERG11. Consequently, RVCZ has considerable potential for use as a therapeutic agent for multi-azole resistant cryptococcosis.
雷夫康唑（RVCZ）自2018年起在日本成为一种新上市的人用唑类药物，是一种广谱抗真菌剂，对白色念珠菌和新型隐球菌（原称：格特隐球菌）具有优异活性。该药物对氟康唑（FLCZ）耐药的分离株也具有高活性。在本研究中，使用临床和实验室标准协会（CLSI）M27 - A3试验，对日本临床分离株和新型隐球菌多唑耐药菌株对雷夫康唑（RVCZ）的体外敏感性进行了研究。14株临床分离株和多唑耐药菌株对RVCZ的最低抑菌浓度分别为0.003125 - 0.125mg/L和0.25 - 0.5mg/L。RVCZ在治疗猫和人的临床分离株方面与伊曲康唑（ITCZ）和伏立康唑（VRCZ）效果相当。此外，RVCZ对在ERG11中编码具有G344S替代蛋白的多唑耐药菌株高度有效。因此，RVCZ作为多唑耐药隐球菌病的治疗药物具有相当大的潜力。
